Home > Boards > US Listed > Biotechs > NantKwest (NK)

I am new to trading since December but

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
kwisatzhaderach Member Profile
 
Followed By 2
Posts 179
Boards Moderated 0
Alias Born 03/21/17
160x600 placeholder
NantKwest Launches First-in-class, First-in-human Phase I Clinical Trial With a Targeted PD-L1 t-haNK Cell Therapy in Patient... Business Wire - 6/24/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/10/2019 4:04:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:48:53 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:45:10 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:42:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:40:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/7/2019 4:36:37 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 6/7/2019 4:32:37 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/7/2019 4:07:44 PM
Cheryl Cohen Appointed to NantKwest’s Board of Directors Business Wire - 6/6/2019 4:10:00 PM
NantKwest Announces Durable Complete Responses in Multiple Advanced-Stage Solid Tumor Cancers Following Off-the-Shelf NK Cell... Business Wire - 6/4/2019 8:00:00 AM
NantKwest Announces Updated Clinical Results for Nanatinostat (VRx-3996), a Novel HDAC Inhibitor Being Developed in Partnersh... Business Wire - 6/4/2019 7:45:00 AM
NantKwest Launches First-in-Human Targeted NK Phase I Clinical Trial of CD19 T-haNK Cell Therapy in Lymphoma Patients Business Wire - 6/3/2019 2:50:00 PM
NantKwest to Present and Provide Update at Upcoming Jefferies 2019 Annual Healthcare Conference Business Wire - 6/3/2019 8:00:00 AM
NantKwest, NantCell & NantOmics to Provide Updated Preclinical & Clinical Data in Four Abstracts at Part of the American Soci... Business Wire - 5/31/2019 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 4:10:11 PM
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92®... Business Wire - 5/1/2019 8:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/26/2019 4:13:38 PM
Amended Statement of Beneficial Ownership (sc 13d/a) Edgar (US Regulatory) - 4/1/2019 4:09:04 PM
NantKwest Announces New haNK Natural Killer Cell Patent Issuance Further Expanding Intellectual Property Estate Business Wire - 4/1/2019 8:00:00 AM
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong Exercises $39 Million in Warrants & Options in Support of NK’s Natural Kil... Business Wire - 3/25/2019 8:00:00 AM
NantKwest Chairman & CEO Dr. Patrick Soon-Shiong to Present Vision for Next Generation Natural Killer Cell Therapies During K... Business Wire - 3/18/2019 5:00:00 AM
Annual Report (10-k) Edgar (US Regulatory) - 3/13/2019 4:09:58 PM
NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Target... Business Wire - 3/4/2019 8:00:00 AM
NantKwest Announces Launch of Merkel Cell Carcinoma Phase II Trial Deploying Novel Triple Combination of off-the-Shelf Natura... Business Wire - 1/9/2019 8:00:00 AM
kwisatzhaderach   Wednesday, 06/14/17 09:08:55 AM
Re: stocktrademan post# 1127
Post # of 1169 
I am new to trading since December but based on my limited knowledge of studying stocks I believe this one can hit 7.77 relatively soon

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist